Clinical Intramuscular Gene Transfer Trial of rAAVrh74.MCK.Micro-Dystrophin to Patients With Duchenne Muscular Dystrophy
| Status: | Completed |
|---|---|
| Conditions: | Neurology, Orthopedic |
| Therapuetic Areas: | Neurology, Orthopedics / Podiatry |
| Healthy: | No |
| Age Range: | 7 - Any |
| Updated: | 11/25/2017 |
| Start Date: | March 2015 |
| End Date: | September 2017 |
Phase I Gene Transfer Clinical Trial for Duchenne Muscular Dystrophy Using rAAVrh74.MCK.Micro-dystrophin
The proposed phase I clinical trial is a pilot study to evaluate safety and biological
activity of the rAAVrh74.MCK.micro-Dystrophin vector administered by an intramuscular route.
This study will evaluated the micro-Dystrophin vector as a potential dystrophin replacement
mechanism for Duchenne Muscular Dystrophy. Two cohorts will undergo gene transfer in a
standard three-six dose escalation scheme to establish maximum tolerated dose (MTD) using
toxicity. A minimum of three subjects will be enrolled into each cohort. The first cohort
will receive a total dose of 3E11 vg. The second cohort will receive 1E12 vg total dose.
activity of the rAAVrh74.MCK.micro-Dystrophin vector administered by an intramuscular route.
This study will evaluated the micro-Dystrophin vector as a potential dystrophin replacement
mechanism for Duchenne Muscular Dystrophy. Two cohorts will undergo gene transfer in a
standard three-six dose escalation scheme to establish maximum tolerated dose (MTD) using
toxicity. A minimum of three subjects will be enrolled into each cohort. The first cohort
will receive a total dose of 3E11 vg. The second cohort will receive 1E12 vg total dose.
The primary objective of this study is the assessment of the safety of an intramuscular
administration of rAAVrh74.MCK.micro-Dystrophin to the Extensor Digitorum Brevis (EDB) muscle
of patients with Duchenne Muscular Dystrophy (DMD). Safety will be assessed by changes in
hematology, serum chemistry, urinalysis, immunologic response to rAAVrh74 and
micro-Dystrophin protein, and reported history and observations of symptoms. Subjects will be
evaluated at baseline, injection visit (days 0-2), and return for follow up visits on days 7,
14, 30,60, 90, and 180 and at the end of 1st and 2nd years. On Day 180, subjects will undergo
a muscle biopsy on the injected muscles in one foot compared with placebo-treatment in the
opposite foot to establish transgene expression and any potential toxicity from gene
transfer.
administration of rAAVrh74.MCK.micro-Dystrophin to the Extensor Digitorum Brevis (EDB) muscle
of patients with Duchenne Muscular Dystrophy (DMD). Safety will be assessed by changes in
hematology, serum chemistry, urinalysis, immunologic response to rAAVrh74 and
micro-Dystrophin protein, and reported history and observations of symptoms. Subjects will be
evaluated at baseline, injection visit (days 0-2), and return for follow up visits on days 7,
14, 30,60, 90, and 180 and at the end of 1st and 2nd years. On Day 180, subjects will undergo
a muscle biopsy on the injected muscles in one foot compared with placebo-treatment in the
opposite foot to establish transgene expression and any potential toxicity from gene
transfer.
Inclusion Criteria:
- Age 7 or older; must be wheelchair-dependent
- Confirmed Dystrophin mutations based on mutation compatibility with micro-dys cDNA
based on previously published methods.
- Males of any ethnic group will be eligible.
- Ability to cooperate with muscle testing.
- Willingness of sexually active subjects with reproductive capacity to practice
reliable method of contraception (If appropriate).
Exclusion Criteria:
- Active viral infection based on clinical observations.
- Symptoms or signs of cardiomyopathy, including:
- Dyspnea on exertion, pedal edema, shortness of breath upon lying flat, or rales
at the base of the lungs
- Echocardiogram with ejection fraction below 40%
- Serological evidence of HIV infection, or Hepatitis A, B or C infection
- Diagnosis of (or ongoing treatment for) an autoimmune disease
- Concomitant illness or requirement for chronic drug treatment that in the opinion of
the PI creates unnecessary risks for gene transfer.
- Subjects with AAVrh74 binding antibody titers ≥ 1:50 as determined by ELISA
immunoassay.
- Abnormal laboratory values in the clinically significant range as defined in protocol
or based upon normal values in the Nationwide Children's Hospital Laboratory.
We found this trial at
1
site
Nationwide Children's Hospital At Nationwide Children’s, we are creating the future of pediatric health care....
Click here to add this to my saved trials
